Live Price Coverage: It Seems Genocea Biosciences Inc Will Go Up. Have Another Big Increase

Live Price Coverage: It Seems Genocea Biosciences Inc Will Go Up. Have Another Big Increase

The stock of Genocea Biosciences Inc (NASDAQ:GNCA) is a huge mover today! About 343,129 shares traded hands. Genocea Biosciences Inc (NASDAQ:GNCA) has declined 17.94% since March 10, 2016 and is downtrending. It has underperformed by 25.46% the S&P500.
The move comes after 9 months positive chart setup for the $109.63 million company. It was reported on Oct, 13 by We have $8.85 PT which if reached, will make NASDAQ:GNCA worth $128.27M more.

Analysts await Genocea Biosciences Inc (NASDAQ:GNCA) to report earnings on November, 3. They expect $-0.42 EPS, down 13.51% or $0.05 from last year’s $-0.37 per share. After $-0.39 actual EPS reported by Genocea Biosciences Inc for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.

Genocea Biosciences Inc (NASDAQ:GNCA) Ratings Coverage

Out of 4 analysts covering Genocea Biosciences (NASDAQ:GNCA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genocea Biosciences has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, September 29 by PiperJaffray. Piper Jaffray maintained Genocea Biosciences Inc (NASDAQ:GNCA) rating on Thursday, August 6. Piper Jaffray has “Overweight” rating and $19 price target. The stock has “Outperform” rating given by FBR Capital on Monday, October 19. Needham maintained the shares of GNCA in a report on Thursday, September 29 with “Buy” rating. On Tuesday, August 11 the stock rating was maintained by Needham with “Buy”. The firm has “Buy” rating by Needham given on Tuesday, October 20. The company was initiated on Thursday, December 17 by UBS.

According to Zacks Investment Research, “Genocea Biosciences, Inc. is involved in developing vaccines. The company’s proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts.”

More important recent Genocea Biosciences Inc (NASDAQ:GNCA) news were published by: which released: “Why It’s Been a Wild Few Days for Genocea Biosciences Inc.” on April 01, 2016, also published article titled: “Genocea Biosciences Posts Positive Herpes Trial Results”, published: “Why Genocea Biosciences Inc Stock Dropped Today” on July 30, 2015. More interesting news about Genocea Biosciences Inc (NASDAQ:GNCA) was released by: and their article: “Genocea Biosciences Shares Dive as Vaccine Candidate Misses Goals” with publication date: October 19, 2015.

GNCA Company Profile

Genocea Biosciences, Inc., incorporated on August 16, 2006, is a biopharmaceutical company. The Firm discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses. The Company’s ATLAS discovery platform is designed to overcome the challenges associated with developing vaccines that stimulate T cell immunity. The Company’s ATLAS is a throughput system for T cell vaccine and immunotherapy discovery. The Firm operates through business of developing and commercializing vaccines segment. The Firm has one product candidate in Phase II clinical development: GEN-003.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment